tradingkey.logo

Evolus Inc

EOLS
View Detailed Chart

6.420USD

-0.100-1.53%
Close 09/18, 16:00ETQuotes delayed by 15 min
414.98MMarket Cap
LossP/E TTM

Evolus Inc

6.420

-0.100-1.53%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.53%

5 Days

-14.51%

1 Month

-4.04%

6 Months

-51.66%

Year to Date

-41.85%

1 Year

-60.42%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
63 / 175
Overall Ranking
183 / 4721
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
19.286
Target Price
+195.79%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 79.17% year-on-year.
Overvalued
The company’s latest PE is -6.62, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 58.85M shares, decreasing 3.78% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.31M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.68.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Ticker SymbolEOLS
CompanyEvolus Inc
CEOMr. David Moatazedi
Websitehttps://www.evolus.com/
KeyAI